Moderna Signs Licensing Deal With Generation Bio in Push Beyond COVID

Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio’s shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash […]

Moderna Plots Vaccines Against 15 Pathogens with Future Pandemic Potential

Moderna Inc said on Monday it plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. The U.S. biotechnology company also said it will make its messenger RNA (mRNA) technology available […]

Moderna Predicts Boost to Sales from COVID-19 Turning Endemic

Moderna Inc on Thursday projected higher vaccine sales for the second half of the year as it sees COVID-19 becoming a flu-like endemic illness, prompting people to take regular shots. The company expects $19 billion in sales of its vaccine this year from $18.5 billion previously and said talks were ongoing for vaccine orders in […]

Moderna Begins Late-Stage Study of RSV Vaccine Using mRNA Technology

Moderna Inc said on Tuesday it had begun a late-stage study of its vaccine for Respiratory Syncytial Virus (RSV) based on the same technology used to develop its COVID-19 shots. The only approved product using messenger RNA (mRNA)is COVID-19 vaccine, but Moderna and rival Pfizer are rushing to tap the potential of the technology to […]